Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

New Survey: Health Care Leaders Say Need For Reform Is Urgent; Broadly Support Public Health Care Option, Provider Payment Reform
By a wide margin, health care leaders believe that individuals should have a choice of public and private health plans, and strongly support other central components of health reform such as innovative provider payment reform and a national insurance health exchange with strong standard-setting authority. In addition, two-thirds (68%) of opinion leaders feel it is urgent to enact comprehensive health care reform this year, according to the latest Commonwealth Fund/Modern Healthcare Health Care Opinion Leaders Survey.

$10 Million European Community Water And Sanitation Project Underway In Iraq; UNICEF Relocates Country Office To Baghdad
- A $10 million project funded by the European Community to improve Iraq"s water and sanitation services is underway. Implemented by UNICEF in collaboration with the Ministry of Municipalities and Public Works and the Ministry of Municipalities in Kurdistan, the project will increase the government"s provision of services as well as strengthen their capacity to manage and develop Iraq"s water and sanitation sector.
News of the day
Women Who Quit Smoking Early In Pregnancy Reduce Risks Of Preterm Birth, Stunted Fetal Growth
Pregnant women who quit smoking during the first trimester and women who never smoked during pregnancy have a similar risk of delivering preterm or very small infants, according to a study published in the journal Obstetrics and Gynecology, Reuters reports. Premature delivery and stunted infant growth are the most well-documented side effects of smoking during pregnancy, and the risks increase for older women, according to study author Laura Polakowski of the Centers for Disease Control and Prevention and colleagues. For the study, the researchers analyzed 915,441 birth certificates for infants born in 2005 in 11 states that include information on whether the woman smoked during pregnancy.The study found that 10% of women who smoked for the entire pregnancy gave birth to "preterm but not too small for gestational age" infants, compared with 8% of women who quit during the first trimester. Fifteen percent of women who smoked the entire pregnancy gave birth to full-term infants who were small for their gestational age, while 2% gave birth to premature infants who were small for gestational age. Among women who quit smoking during the first trimester, these outcomes occurred 9% and 1% of the time, respectively.After adjusting for the women"s age, previous preterm births and other factors, the researchers found that women who quit smoking in the first trimester reduced their risk of giving birth to a preterm, normal-size infant by 31%. The risk of delivering a full-term, unusually small infant was cut by 55% and the risk for delivering a preterm, unusually small infant was reduced by 53%. The risks were also reduced for women who quit smoking during their second trimester, although less significantly. The researchers found that the risk reduction was particularly high for older women -- especially those older than age 40 -- who quit smoking during the first trimester. According to the study, the results indicate that the risk of delivering a preterm or small-for-gestational-age infant for pregnant women who quit smoking during the first trimester is "comparable to those who never smoke during pregnancy" (Reuters, 7/21).
Cardiovascular

AstraZeneca Submits New Drug Applications For ZACTIMA(TM) In Second-Line Advanced Non-Small Cell Lung Cancer

AstraZeneca (NYSE: AZN) announced the company has submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) and a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMEA) for an investigational drug, vandetanib 100 mg for use in combination with chemotherapy for the treatment of advanced non-small cell lung cancer in patients previously treated with one prior anti-cancer therapy. The U.S. and European submissions are supported by data from Phase III clinical studies evaluating the safety and efficacy of vandetanib 100 mg in combination with chemotherapy. Pending approval, the treatment will be marketed as ZACTIMA(TM). Evaluation of vandetanib is ongoing, as monotherapy or in combination with other anti-cancer therapies in a range of tumour types, including thyroid cancer. Results from the ZEPHYR (300mg monotherapy study in EGFR failures in advanced NSCLC, Phase III) and ZETA (300 mg monotherapy in advanced medullary thyroid cancer, Phase III) studies will be presented in the first half of 2010. Howard Hutchinson, MD, Chief Medical Officer at AstraZeneca said, "Lung cancer is an area of high unmet need and these submissions are an important step toward potentially broadening the treatment options available for patients." About Vandetanib Vandetanib has a unique profile that fights cancer through two clinically proven mechanisms -- by blocking the development of tumour blood supply (anti-angiogenesis or anti-VEGFR), and by blocking the growth and survival of the tumour itself (anti-EGFR). Vandetanib also inhibits RET-tyrosine kinase activity, an important growth driver in certain types of thyroid cancer. About Vandetanib Phase III Studies ZODIAC (ZACTIMA in cOmbination with Docetaxel In non-smAll cell lung Cancer) is a Phase III randomised, double-blind, placebo-controlled study evaluating the combination of vandetanib 100mg once daily plus docetaxel versus docetaxel alone in patients with locally advanced or metastatic NSCLC, treated with one prior anti-cancer therapy. It enrolled 1391 patients at 250 centres throughout Europe, North America, South America and Asia Pacific. ZEAL (ZACTIMA Efficacy with Alimta in Lung cancer) is a randomised, double-blind, placebo-controlled Phase III study evaluating the combination of vandetanib 100mg with pemetrexed versus pemetrexed alone in patients with locally advanced or metastatic NSCLC, treated with one prior anti-cancer therapy. It enrolled 534 patients at 160 centres across 23 countries. ZEST (ZACTIMA Efficacy Study versus Tarceva) is a Phase III randomised, double-blind, multi-centre study to assess the efficacy of vandetanib 300mg versus erlotinib in patients with locally advanced or metastatic NSCLC after failure of at least one prior anti-cancer therapy. It enrolled 1240 patients at 171 centres across 22 countries. ZEPHYR (ZACTIMA Efficacy trial for NSCLC Patients with HistorY of EGFR-TKI and chemo-Resistance) is a Phase III, randomised, double-blind, parallel-group, multi-centre study evaluating the efficacy of ZACTIMA 300mg plus best supportive care versus best supportive care in patients with locally advanced or metastatic (stage IIIB-IV) NSCLC after prior therapy with an EGFR inhibitor. The study is running in approximately 170 centres across 23 countries. ZETA (Zactima Efficacy in Thyroid Cancer Assessment) is a phase III, randomized, double-blind, placebo-controlled, multi-centre study, evaluating once-daily ZACTIMA 300mg as a monotherapy in advanced medullary thyroid cancer. About lung cancer -- Over 1.35 million new cases of lung cancer are diagnosed every year and nearly 1.2 million people die as a result of this devastating disease -- more than breast, colon and prostate cancer combined(i) -- Non-small cell lung cancer accounts for around 85% of all lung cancers(ii) -- If lung cancer is detected at early stages, before it has spread to other organs or lymph nodes, around half of patients can survive for five years or more. However, few lung cancers are found at this early stage and it is normally diagnosed at the advanced stage, when five year survival falls to approximately 15%(iii) About AstraZeneca AstraZeneca is engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and in the supply of healthcare services. AstraZeneca is one of the world"s leading pharmaceutical companies with global healthcare sales of $ 31.6 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. In the United States, AstraZeneca is a $13.5 billion dollar healthcare business. (i) Ferlay, J. et al. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase No. 5. version 2.0. Lyon: IARC Press, 2004. (ii) Ginsberg RJ. et al. Cancer: Principles and Practices of Oncology. 5(th) ed; 858-911. 1997. 6(th) ed. 925-983. 2001. (iii) Bepler G. Lung cancer epidemiology and genetics. J Thorac Imaging 1999; 14(4):228-234. AstraZeneca


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009